These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 33670427)

  • 21. YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis.
    Cho H; Kim J; Ahn JH; Hong YK; Mäkinen T; Lim DS; Koh GY
    Circ Res; 2019 Jan; 124(2):225-242. PubMed ID: 30582452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common and Unique Transcription Signatures of YAP and TAZ in Gastric Cancer Cells.
    Lee Y; Finch-Edmondson M; Cognart H; Zhu B; Song H; Low BC; Sudol M
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33297432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. YAP/TAZ: a promising target for squamous cell carcinoma treatment.
    Dong X; Meng L; Liu P; Ji R; Su X; Xin Y; Jiang X
    Cancer Manag Res; 2019; 11():6245-6252. PubMed ID: 31360073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circ0106714 inhibits tumorigenesis of colorectal cancer by sponging miR-942-5p and releasing DLG2 via Hippo-YAP signaling.
    Li S; Yan G; Liu W; Li C; Wang X
    Mol Carcinog; 2020 Dec; 59(12):1323-1342. PubMed ID: 33128289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of miR-15a expression by tripterygium glycosides caused premature ovarian failure by suppressing the Hippo-YAP/TAZ signaling effector Lats1.
    Ai A; Xiong Y; Wu B; Lin J; Huang Y; Cao Y; Liu T
    Gene; 2018 Dec; 678():155-163. PubMed ID: 30092342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
    Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
    Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WIP, YAP/TAZ and Actin Connections Orchestrate Development and Transformation in the Central Nervous System.
    Antón IM; Wandosell F
    Front Cell Dev Biol; 2021; 9():673986. PubMed ID: 34195190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations.
    Yamaguchi H; Taouk GM
    Front Oncol; 2020; 10():928. PubMed ID: 32596154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-Functional Regulation by YAP/TAZ Signaling Networks in Tumor Progression and Metastasis.
    Thrash HL; Pendergast AM
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression.
    Luu AK; Schott CR; Jones R; Poon AC; Golding B; Hamed R; Deheshi B; Mutsaers A; Wood GA; Viloria-Petit AM
    BMC Vet Res; 2018 Nov; 14(1):365. PubMed ID: 30477496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1.
    Ando T; Arang N; Wang Z; Costea DE; Feng X; Goto Y; Izumi H; Gilardi M; Ando K; Gutkind JS
    Commun Biol; 2021 Nov; 4(1):1237. PubMed ID: 34725466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma.
    Liu Y; Wang X; Yang Y
    Clin Mol Hepatol; 2020 Oct; 26(4):742-750. PubMed ID: 32981290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck.
    Santos-de-Frutos K; Segrelles C; Lorz C
    J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hippo Signaling in Cancer: Lessons From
    Snigdha K; Gangwani KS; Lapalikar GV; Singh A; Kango-Singh M
    Front Cell Dev Biol; 2019; 7():85. PubMed ID: 31231648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting.
    Lo Sardo F; Strano S; Blandino G
    Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29734788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Hippo signaling pathway provides novel anti-cancer drug targets.
    Bae JS; Kim SM; Lee H
    Oncotarget; 2017 Feb; 8(9):16084-16098. PubMed ID: 28035075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises.
    Ortega Á; Vera I; Diaz MP; Navarro C; Rojas M; Torres W; Parra H; Salazar J; De Sanctis JB; Bermúdez V
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional co-activators YAP1-TAZ of Hippo signalling in doxorubicin-induced cardiomyopathy.
    Berecz T; Yiu A; Vittay O; Orsolits B; Mioulane M; Dos Remedios CG; Ketteler R; Merkely B; Apáti Á; Harding SE; Hellen N; Foldes G
    ESC Heart Fail; 2022 Feb; 9(1):224-235. PubMed ID: 34931757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of YAP/TAZ-Notch1-NICD axis by bromodomain and extraterminal protein inhibition impairs liver regeneration.
    Liu C; Cheng X; Chen J; Wang Y; Wu X; Tian R; Liu B; Ding X; Sun Q; Gong W
    Theranostics; 2019; 9(13):3840-3852. PubMed ID: 31281517
    [No Abstract]   [Full Text] [Related]  

  • 40. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
    Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
    J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.